P656: Are trough levels of anti-TNF drugs related with treatment failure and duration of treatment?ECCO '18 Vienna
2018
P657: Postoperative outcome in Crohn’s disease: Observational study of 1283 surgical patientsECCO '18 Vienna
2018
P658: Faecal calprotectin is capable of predicting mucosal healing in paediatric-onset Crohn’s disease patients under sustained clinical remission with biologicsECCO '18 Vienna
2018
P659: FMT as a treatment for IBD: A national survey of gastroenterologists in the UKECCO '18 Vienna
2018
P660: A pilot elastography study in patients with inflammatory bowel disease on long-term treatment with azathioprineECCO '18 Vienna
2018
P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologicsECCO '18 Vienna
2018
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registryECCO '18 Vienna
2018
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumabECCO '18 Vienna
2018
P665: Higher BMI but not systemic immune suppression increases the risk of short-term postoperative complications in Crohn’s disease patientsECCO '18 Vienna
2018
P666: Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA RegistryECCO '18 Vienna
2018
P667: Standard vs. intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel diseaseECCO '18 Vienna
2018
P668: Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBDECCO '18 Vienna
2018
P669: Human β-defensin 2 suppresses TNF-α secretion in human and mouse dendritic cells mediated by chemokine receptor-2ECCO '18 Vienna
2018
P670: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysisECCO '18 Vienna
2018
P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumabECCO '18 Vienna
2018
P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel diseaseECCO '18 Vienna
2018